Clinical Trial

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-term radiotherapy, sequential Camrelizumab and CAPOX (group A) to long-term concurrent chemoradiotherapy, sequential CAPOX (group B) in patients with LARC. A total of 230 patients were included in this study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-06-14; most recent amendment 2026-02-24.
Status change: Recruiting → Active, Not Recruiting 2023-12-31
Status change: Not Yet Recruiting → Recruiting 2021-07-20
Trial Details
NCT Number NCT04928807
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Rectal Cancer
Enrollment 231 participants
Start Date 2021-07-20
Primary Completion 2023-03-01 (estimated)
Study Completion 2028-03-20 (estimated)
Updated on ClinicalTrials.gov 2026-02-27